Global Biopharmaceutical M&A and VC Insights
The life sciences industry continues to undergo significant transformation, with companies navigating through portfolio risks, pipeline challenges, public policy, and economic uncertainty. Our latest report reflects on mergers and acquisitions (M&A) trends and venture capital (VC) trends over the past year and provides considerations for biopharmaceutical companies heading into 2025. Discover the key insights below:
M&A activity has been subdued relative to 2023 with companies prioritizing growth and innovation
Acquirers continue to target pre-clinical therapeutics within oncology and central nervous systems (CNS) therapeutic areas
Cell and gene therapies (CGT) and anti-drug conjugates (ADCs) continue to be popular technology targets, with mRNA therapies gaining traction
VC dealmaking continues to remain steady, with 2024 deal volume tracking similarly to 2023
VC deals continue to concentrate around early-stage funding, reflecting a focus on novel innovative technologies
Biotech IPOs in 2024 to date have nearly doubled in volume relative to 2023, indicating acclimation to interest rates generally holding steady